Updated hourlyHourly refreshWed, Sep 2, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare
Corline Biomedical AB intensifierar sin kommersiella satsning på den amerikanska marknaden för att ta tillvara det momentum som skapats efter FDA-godkännandet av Kardiums Globe® Pulsed Field System. Satsningen omfattar förstärkta resurser inom Corlines befintliga amerikanska agentstruktur, en ökad marknadsnärvaro samt ett förenklat och standardiserat erbjudande för medicinteknikbolag som vill utvärdera CHS™. Målet är att rekrytera och/eller konvertera ytterligare 3–5 betydande kunder till kommersiell fas till år 2029.
Aug 26 · 06:11·GlobeNewswire
Healthcare
'The Devil In Bethel: How to Discern Satan's Demonic Teachers, Prophets, Idols, and Tools in God's Church' released RANCHO CUCAMONGA, Calif., Aug. 26, 2026 /PRNewswire/ -- Christian clinical counselor Aaron G. Cisneros invites believers to take a closer look at biblical discernment in...
Aug 26 · 04:00·PR Newswire
Healthcare
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The protocol amendment for the pivotal Phase...
Aug 26 · 01:24·PR Newswire
Finance · AI
HONG KONG, August 26, 2026 - (ACN Newswire) - FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced interim results for the six months ended 30 June 2026[1].
- New business sales were up seven per cent on the prior corresponding period to US$1.35 billion on an annualised premium equivalent (APE) basis. New business contractual service margin was US$996 million, with year-on-year growth of 25 per cent.
- Operating profit after tax was up 20 per cent to US$298 million with positive contributions from all four reportable segments: Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Expansion Markets. Net profit after tax of US$172 million was a three-fold increase on the first half of 2025 and represents another record result.
- Shareholder value creation indicators continued to trend positively, with comprehensive tangible equity up five per cent to US$8.83 billion and Group embedded value up five per cent to US$6.95 billion compared to 31 December 2025. FWD Group retained a solvency ratio[2] of 203 per cent, after the adoption of economic value-based solvency regulation in Japan.
- Announced a key hire in May for the high-net-worth (HNW) business, which serves the global HNW insurance market with diversified asset allocation, wealth management, and legacy planning.
- Received globally recognised certification in July for the development, procurement, deployment, and use of artificial intelligence (AI) systems, reflecting the growing maturity and responsible use of AI at FWD Group with the ISO/IEC 42001 standard achieved from the International Organisation for Standardisation/International Electrotechnical Commission.
Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “FWD Group had a very strong start to our first full year as a listed company. Once again, we’ve demonstrated our ability to sustain growth, and to convert that growth into rising bottom-line profitability, while expanding margins. This was driven by the diversification built into our geographic footprint and multi-channel distribution model over the past 13 years, as well as a capital structure that positions FWD Group well for the future.”
In the company’s home market of Hong Kong SAR, momentum continued despite record prior-year growth, supported by resilient domestic demand and the city’s role as one of the world’s largest cross-border wealth hubs.
Excellent growth in Japan was driven by the company’s expansion into the savings and retirement needs segment in July 2025, complementing its existing protection business as a rapidly ageing society continues to fuel the longevity economy.
In Thailand, the focus on profitable new business continued in the company’s market-leading exclusive bancassurance partnership with Siam Commercial Bank and agency distribution channels. The transition to a new Chief Executive Officer for Thailand was completed in May when Khun Knattapisit Krutkrongchai (KK) joined the company.
Strong growth in Expansion Markets – comprised of Indonesia, Malaysia, the Philippines, Singapore, and Vietnam – was achieved despite the macroeconomic uncertainty in some countries in this segment.
“These results are the latest example of the strong track record we’re building as a listed company serving more than 40 million customers across 10 markets in Asia. At FWD Group, we remain heavily focused on anchoring around the customer – aided by the golden age of transformational technological innovation that we’re living in,” added Huynh Thanh Phong.
Across the region, 21 new products were introduced in the first half of 2026 in response to emerging customer needs. The FWD Group consumer outlook survey released in February 2026, prior to the outbreak of conflict in the Middle East and the associated global energy economic shocks, showed that most of Asia’s middle-class feel financially anxious and underprepared for retirement.
About FWD Group
FWD Group (1828.HK) is a pan-Asian life and health insurance business that serves over 40 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the Hong Kong Stock Exchange under the stock code 1828. For more information, please visit www.fwd.com
For media inquiries, please contact: groupcommunications@fwd.com
Source: FWD Group Holdings Limited
[1] The results are for the six months ended 30 June 2026 and are compared to the same period in 2025. Growth rates are represented on a constant exchange rate (CER) basis. The results are based on the unaudited interim condensed consolidated financial statements and embedded value supplementary report for the first half of 2026, unless otherwise stated. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 per cent annualised first year premiums and 10 per cent single premiums. Group LCSM cover ratio, group embedded value and comprehensive tangible equity 2025 values are December 2025 balances/ratios and growth rates are shown accordingly.
[2] Prescribed capital requirement (PCR) basis
Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Aug 25 · 23:32·mlpr-acnnewswire
Finance · Healthcare
NEW YORK, August 25, 2026--Concordare converts clinical trial protocols into a digital format, automating workflows that reduce the time, cost and error rate of clinical trials.
Aug 25 · 23:10·mlpr-businesswire
Finance · Healthcare
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 25 · 23:06·GlobeNewswire
Healthcare
HOLLYWOOD, Fla., Aug. 25, 2026 /PRNewswire/ -- Memorial Healthcare System has named Irfan Mirza as its Chief Financial Officer, recognizing his leadership in aligning Memorial's financial strategy with its mission to deliver exceptional patient care, support strategic growth and...
Aug 25 · 22:51·PR Newswire
Healthcare
SYDNEY, August 25, 2026--Avetta®, the leader in intelligent work readiness across global supply chains, today announced the appointment of Lynda Richards as APAC Principal, Health and Safety. Richards will work across Avetta's Risk Advisory, Product Management and regional leadership teams to strengthen the company's health and safety capabilities and help shape innovation that addresses the evolving needs of businesses across APAC.
Aug 25 · 22:00·mlpr-businesswire
Healthcare
Frederick-area businesses push annual fundraiser for Frederick Health Hospice toward its $5,000 goal FREDERICK, Md., Aug. 25, 2026 /PRNewswire/ -- American Iron Speed-n-Cycle has raised more than $4,000 for Frederick Health Hospice through community sponsorships for the 2nd Annual Miles...
Aug 25 · 22:00·PR Newswire
Healthcare
MINNEAPOLIS, August 25, 2026--Padilla names new Health sector leaders, strengthening its integrated expertise and positioning the agency for continued growth.
Aug 25 · 21:49·mlpr-businesswire
Healthcare
(PR-inside.com) Federal courts are confronting allegations that major MSOs marketed recreational cannabis as medicine without FDA clinical trials, while MMJ's cases challenge a system that penalized the company that followed the federal drug-development pathway. WASHINGTON, D.C. / ACCESS Newswire / August 25, 2026 / MMJ International Holdings today called attention to a rapidly developing collision between federal marijuana policy, unsupported medical marketing allegations and insurance coverage that could have consequences across the cannabis industry. As DEA Administrative Law Judge Derek C. Julius considers his recommendation in the federal marijuana-rescheduling proceeding-and federal courts consider MMJ-related challenges-major cannabis multistate operators are facing proposed class a
Aug 25 · 21:45·PR-Inside
Healthcare
Federal courts are confronting allegations that major MSOs marketed recreational cannabis as medicine without FDA clinical trials, while MMJ's cases challenge a system that penalized the company that followed the federal drug-development pathway.
Aug 25 · 21:45·Newswire.com